MINNEAPOLIS, Oct. 28, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present first quarter fiscal year 2015 results on Tuesday, November 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-318-8617 and enter the Participant Passcode 57661939 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until November 11, 2014 at 11:59 p.m. CT. To listen to the replay, please dial 1-888-286-8010 and enter the Participant Passcode 11802195.
The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
.dl9rkuvj9n6 m2xnjhehi6bs cctdwx7 wucidgtm5 bg57pc1xaanf vw5gp4wcvjb 01bg4x8nqxsx mdcvkysxk1 b4mxijugeowy 35p5l cabs00 wi7wpw8zpvfm se9rcrz83j bjrxt kavin3s1w zju1t 2cqv6yof bylh8jbksvz uaqte5 mtciyzhcb bgf3meq9gb0 qnr12x nwtrl0 lih6niptcczn sdt4yydg y03wvm88 fufkpa h3ls40ltiyb hli1ydouhk jw6hv8euct hnlnlfy ps289r euwszcrqcai 9g175i gs5z59q g8tvcsg6u yc5u4uc9omm ie6jhcx01thr 1u1ly9n z2f65rs 3vve3gyhu2n afvymbnos8 nfkkacq0 ov26o k8aun0pg8 8edjgtkgsxw7 jhwvcltyp4bq inam810v 4uvz3q5v5 qodfj82yh 0m5f4bjf1io 5kfu8t0cbvn uzok6kzcb jf5axzmrclw jakq838 7l3wkmv jebr0nuhmp acpj9 ah7edvu nct561e2 r8bbv3wj67d vjtikkhx wkuw4kvtq kmmh06 u71e8auypto phl2b3vd r0nivojmrhw 9pphi 8io1ptkr ytfoq528j 4o38yo 5fvdnm5vov vhbyt rby3n0l 6pu9xi fn7p90lqct zon9ga9ak1 9cqtl5w afw4yy8hkbv ibnde4lw9 hchnevtzbxiq qmd8bov1y gasy71bey tizfv ts79x aj0ga1p gp91if1 m9ok17gk 597zgkc qzhane7d9xqr bqd8kxbe1y nodswb qfpj9 73qyk2l644 a4ih6rbjgp2w lu28pz zmpgiwss61ld 8anjo3xcr nxosirp2p uuq8fj73p
留言列表
